{"id":335335,"date":"2019-11-02T01:00:00","date_gmt":"2019-11-02T00:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/le-pembrolizumab-en-traitement-de-premiere-ligne-reduit-le-taux-de-mortalite\/"},"modified":"2019-11-02T01:00:00","modified_gmt":"2019-11-02T00:00:00","slug":"le-pembrolizumab-en-traitement-de-premiere-ligne-reduit-le-taux-de-mortalite","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/le-pembrolizumab-en-traitement-de-premiere-ligne-reduit-le-taux-de-mortalite\/","title":{"rendered":"Le pembrolizumab en traitement de premi\u00e8re ligne r\u00e9duit le taux de mortalit\u00e9"},"content":{"rendered":"<p><strong>Dans une \u00e9tude de phase III, le pembrolizumab a am\u00e9lior\u00e9 la survie globale chez des patients atteints de carcinome \u00e9pidermo\u00efde r\u00e9cidivant ou m\u00e9tastatique de la r\u00e9gion t\u00eate et cou.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>L&#8217;\u00e9tude de phase III KEYNOTE-048, pr\u00e9sent\u00e9e lors de la r\u00e9union annuelle de l&#8217;ASCO 2019, a \u00e9valu\u00e9 le pembrolizumab (<sup>KEYTRUDA\u00ae<\/sup>), un inhibiteur de la prot\u00e9ine PD-1 (Programmed Cell Death&nbsp;1 Protein), en monoth\u00e9rapie ou en association avec une chimioth\u00e9rapie dans le traitement de premi\u00e8re ligne du carcinome \u00e9pidermo\u00efde de la t\u00eate et du cou (Head and Neck Squamous Cell Carcinoma, HNSCC) r\u00e9cidivant ou m\u00e9tastatique. Il s&#8217;agit de la premi\u00e8re publication des donn\u00e9es de cette \u00e9tude sur la survie globale sous pembrolizumab en association avec la chimioth\u00e9rapie en fonction de l&#8217;expression de PD-L1 des tumeurs, ainsi qu&#8217;\u00e0 partir du bras pembrolizumab en monoth\u00e9rapie dans le collectif global et ind\u00e9pendamment du statut PD-L1 de la tumeur. L&#8217;analyse int\u00e9rimaire a \u00e9t\u00e9 pr\u00e9sent\u00e9e lors de la r\u00e9union annuelle ESMO 2018. Il en ressort une survie globale sup\u00e9rieure sous pembrolizumab en association avec la chimioth\u00e9rapie dans le collectif global ainsi que sous pembrolizumab en monoth\u00e9rapie chez les patients dont les tumeurs expriment PD-L1 avec un score positif combin\u00e9 (CPS) \u226520 et \u22651 par rapport aux patients sous le traitement standard actuel (sch\u00e9ma EXTREME). La classification des carcinomes \u00e9pidermo\u00efdes se fait selon les syst\u00e8mes TNM actuellement en vigueur de l&#8217;Union internationale contre le cancer (UICC) ou de l&#8217;American Joint Committee on Cancer (AJCC). Selon l&#8217;AJCC, les carcinomes \u00e9pidermo\u00efdes de la r\u00e9gion cervico-c\u00e9phalique sont distingu\u00e9s de ceux des autres localisations.<\/p>\n<p>&nbsp;<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\" size-full wp-image-12595\" alt=\"\" src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2019\/11\/abb_dp5_s48.jpg\" style=\"height:429px; width:600px\" width=\"1100\" height=\"786\"><\/p>\n<p>\n<em>Source : MSD  <\/em><br \/>\n&nbsp;<\/p>\n<p><em>DERMATOLOGIE PRATIQUE 2019 ; 29(5) : 48<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dans une \u00e9tude de phase III, le pembrolizumab a am\u00e9lior\u00e9 la survie globale chez des patients atteints de carcinome \u00e9pidermo\u00efde r\u00e9cidivant ou m\u00e9tastatique de la r\u00e9gion t\u00eate et cou.<\/p>\n","protected":false},"author":7,"featured_media":92034,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Carcinome \u00e9pidermo\u00efde","footnotes":""},"category":[11362,11527,11545,11389,11535,11549],"tags":[14282,24762,15801],"powerkit_post_featured":[],"class_list":["post-335335","post","type-post","status-publish","format-standard","has-post-thumbnail","category-dermatologie-et-venerologie","category-etudes","category-marche-medecine","category-oncologie","category-rapports-de-congres","category-rx-fr","tag-carcinome-epidermoide","tag-keytruda-fr","tag-pembrolizumab-fr","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-23 23:53:55","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":335320,"slug":"il-pembrolizumab-come-terapia-di-prima-linea-riduce-il-tasso-di-mortalita","post_title":"Il pembrolizumab come terapia di prima linea riduce il tasso di mortalit\u00e0","href":"https:\/\/medizinonline.com\/it\/il-pembrolizumab-come-terapia-di-prima-linea-riduce-il-tasso-di-mortalita\/"},"pt_PT":{"locale":"pt_PT","id":335325,"slug":"pembrolizumab-como-terapia-de-primeira-linha-reduz-a-taxa-de-mortalidade","post_title":"Pembrolizumab como terapia de primeira linha reduz a taxa de mortalidade","href":"https:\/\/medizinonline.com\/pt-pt\/pembrolizumab-como-terapia-de-primeira-linha-reduz-a-taxa-de-mortalidade\/"},"es_ES":{"locale":"es_ES","id":335328,"slug":"el-pembrolizumab-como-terapia-de-primera-linea-reduce-la-tasa-de-mortalidad","post_title":"El pembrolizumab como terapia de primera l\u00ednea reduce la tasa de mortalidad","href":"https:\/\/medizinonline.com\/es\/el-pembrolizumab-como-terapia-de-primera-linea-reduce-la-tasa-de-mortalidad\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/335335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=335335"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/335335\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/92034"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=335335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=335335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=335335"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=335335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}